Bayer targets €500m after EU OK for Adempas
This article was originally published in Scrip
Executive Summary
Bayer's orphan drug Adempas (riociguat) has been approved in Europe for two forms of pulmonary hypertension. The company estimates peak annual sales in the two indications could exceed €500m. According to BioMedTracker analysis for Sagient Research, the product could achieve peak sales of around $870m worldwide in 2020.